Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...

AI fundraises, tech partnerships and M&A deals, including DispatchHealth and Medically Home's tie-up, and plans for a potential blockbuste | The first three months of 2025 saw a steady volume of ...

While Hims & Hers offers Zepbound for $1,899 per month, Eli Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. HealthDay News — The telehealth company Hims ...

Hims & Hers now provides access to Zepbound, a brand-name version of the drug tirzepatide, for $1,899 per month. HealthDay News — The telehealth company Hims & Hers Health is expanding its weight-loss ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as generics of Novo Nordisk's diabetes drug liraglutide through its weight loss ...

Investor excitement about news of a fresh product launch ... Zepbound. It's also gearing up to sell biosimilars of Novo Nordisk diabetes treatment liraglutide. Investors plowed into Hims & Hers ...

It’s less “we got Zepbound” and more “look what you could be saving on.” The real news — and it got completely overshadowed — was the official launch of Hims & Hers’ $299/month generic liraglutide, a ...

WEDNESDAY, April 2, 2025 (HealthDay News) — The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform. The company said Tuesday it now ...

Hims is a telehealth platform for men that offers virtual care for various health concerns. The platform addresses issues such as hair loss, sexual health, weight management, skincare and mental ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.